nukliD®, the beating heart of radiopharmacy in Dresden, offers pioneering solutions that drive innovation in nuclear medicine and open up new perspectives for the treatment of cancer. We are a dynamic network of experts and trailblazers who are actively shaping the future of radiopharmacy. Our partner companies in the Dresden area are looking for committed and qualified employees to help shape the future of this innovation cluster.

The nukliD® network unites the renowned partners ABX advanced biochemical compounds GmbH, ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH, CUP Laboratorien Dr. Freitag GmbH, Gamma Service Recycling GmbH, Helmholtz-Zentrum Dresden-Rossendorf e. V., Isotope Technologies Dresden GmbH, MDG Molecular Diagnostics Group GmbH, ROTOP Pharmaka GmbH, and TRIMT GmbH. The network is coordinated by leap:up GmbH.

nukliD® brings together unique expertise in the field of radiopharmacy and offers the advantages of a strong network. The collaboration enables:

• Visibility: Partners discuss measures to increase their visibility, such as events or contributions. biosaxony supports or organises joint appearances, e.g. at (inter)national trade fairs.
• Recruitment, training and further education of skilled workers: Measures to secure, recruit and train skilled workers are jointly identified and coordinated, led by biosaxony.
• Cooperation with public authorities and funding: Development of a position paper on optimising approval processes and generating funding. biosaxony regularly reviews funding opportunities and coordinates with public authorities.
• Technical fundamentals: Coordination to secure radionuclide production and review of funding opportunities by biosaxony.

This close cooperation creates synergies, promotes innovation and strengthens the location.